ArticleAACE endocrinology and diabetes
Sky-High Thyroglobulin Level Following Thyroid Lobectomy Without Evidence of Metastatic Disease.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objective: Thyroglobulin (Tg) serves as a crucial indicator for monitoring recurrence in patients with differentiated thyroid cancer following total thyroidectomy and radioactive iodine therapy. The utility of following Tg after thyroid lobectomy (TL) is debatable. There appears to be insufficient evidence to establish a specific Tg cutoff that can reliably detect persistent or recurrent disease after TL. The objective of this report is to describe a patient with an unexpectedly elevated Tg level following thyroid lobectomy for low-risk papillary thyroid carcinoma. Case Report: A 41-year-old female patient underwent a left thyroid lobectomy for low-risk classic papillary thyroid carcinoma. Her postoperative assessment reveals an unexpectedly elevated Tg at 4055 ng/mL (normal range: 3.5-77 ng/mL) with a negative Tg antibody <22 IU/mL (kIU/L). This is confirmed through repeated tests using multiple techniques to rule out laboratory errors and interference. Metastatic workup, including thyroid sonographic assessment and biopsy, chest computed tomography, and an 18F-fluorodeoxyglucose positron emission tomography scan, yielded negative results. Following thyroidectomy, the Tg level decreases dramatically to 0.7 ng/mL (0.7 μg/L). Discussion: Significantly elevated Tg levels after TL warrant careful consideration, but it is crucial to exclude potential laboratory errors and assay interference; additionally, it is essential to rule out underlying metastatic disease. Conclusion: Measuring Tg and Tg antibody levels post-TL can provide a baseline for future reference. However, this case illustrates that high levels of Tg can be seen in the absence of thyroid cancer and therefore cannot reliably predict the risk of recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.